Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine.

Abstract

Posttreatment exacerbation of hepatitis B virus (HBV) infection in long-term HBV trials of emtricitabine occurred in 23% of patients. Development of antibody to hepatitis e antigen did not prevent hepatic flare. One patient with marked bridging fibrosis required liver transplantation. Patients with advanced liver disease are at risk for hepatic flare with decompensation if active treatment is withdrawn (e.g., when highly active antiretroviral treatment is modified).

• Authors: E Mondou, J Sorbel, J Anderson, H Mommeja-Marin, A Rigney, F Rousseau
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 41 Issue 5 Pg. e45-7 (Sep 01 2005) ISSN: 1537-6591 [Electronic] United States
• PMID: 16080074 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• Deoxycytidine
• Emtricitabine

Topics

• Antiviral Agents (administration & dosage, therapeutic use)
• Deoxycytidine (administration & dosage, analogs & derivatives, therapeutic use)
• Disease Progression
• Drug Administration Schedule
• Emtricitabine
• Hepatitis B, Chronic (drug therapy)
• Humans